BR9508751A - Composto formulação e processos de tratamento ou profilaxia de disfunções psicóticas ou disfunções de debilitação intelectual e da ansiedade e de preparação do composto - Google Patents
Composto formulação e processos de tratamento ou profilaxia de disfunções psicóticas ou disfunções de debilitação intelectual e da ansiedade e de preparação do compostoInfo
- Publication number
- BR9508751A BR9508751A BR9508751A BR9508751A BR9508751A BR 9508751 A BR9508751 A BR 9508751A BR 9508751 A BR9508751 A BR 9508751A BR 9508751 A BR9508751 A BR 9508751A BR 9508751 A BR9508751 A BR 9508751A
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- compound
- anxiety
- prophylaxis
- processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 208000019901 Anxiety disease Diseases 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
- 230000036506 anxiety Effects 0.000 title 1
- 230000006735 deficit Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9417084A GB9417084D0 (en) | 1994-08-24 | 1994-08-24 | Compounds useful in therapy |
| GBGB9504627.2A GB9504627D0 (en) | 1995-03-08 | 1995-03-08 | Compounds for use in therapy |
| PCT/SE1995/000937 WO1996006098A1 (en) | 1994-08-24 | 1995-08-22 | Spiro-azabicyclic compounds useful in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9508751A true BR9508751A (pt) | 1997-08-12 |
Family
ID=26305509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9508751A BR9508751A (pt) | 1994-08-24 | 1995-08-22 | Composto formulação e processos de tratamento ou profilaxia de disfunções psicóticas ou disfunções de debilitação intelectual e da ansiedade e de preparação do composto |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US5902814A (pt) |
| EP (1) | EP0777671B1 (pt) |
| JP (1) | JP3708962B2 (pt) |
| KR (1) | KR100366331B1 (pt) |
| CN (2) | CN1056846C (pt) |
| AR (1) | AR031828A2 (pt) |
| AT (1) | ATE192157T1 (pt) |
| AU (1) | AU690735B2 (pt) |
| BR (1) | BR9508751A (pt) |
| CA (1) | CA2196995C (pt) |
| CZ (1) | CZ289512B6 (pt) |
| DE (1) | DE69516524T2 (pt) |
| DK (1) | DK0777671T3 (pt) |
| EE (1) | EE03399B1 (pt) |
| EG (1) | EG24222A (pt) |
| ES (1) | ES2145922T3 (pt) |
| FI (1) | FI112868B (pt) |
| GR (1) | GR3033878T3 (pt) |
| HU (1) | HUT77352A (pt) |
| IL (1) | IL115039A (pt) |
| IS (1) | IS1852B (pt) |
| MX (1) | MX9701292A (pt) |
| NO (1) | NO307707B1 (pt) |
| NZ (1) | NZ292289A (pt) |
| PL (1) | PL183933B1 (pt) |
| PT (1) | PT777671E (pt) |
| RU (1) | RU2148058C1 (pt) |
| SA (1) | SA95160370B1 (pt) |
| SK (1) | SK282366B6 (pt) |
| TR (1) | TR199501053A2 (pt) |
| TW (1) | TW397837B (pt) |
| UA (1) | UA54375C2 (pt) |
| WO (1) | WO1996006098A1 (pt) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| JP4564135B2 (ja) * | 1999-07-26 | 2010-10-20 | 住友化学株式会社 | 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶 |
| WO2001066546A1 (en) * | 2000-03-09 | 2001-09-13 | Mitsubishi Pharma Corporation | Spiro compounds, process for preparing the same and use thereof as drugs |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| JP2004507549A (ja) * | 2000-08-28 | 2004-03-11 | コロラド ステート ユニバーシティー リサーチ ファウンデーション | オキサゾリジノン部分を含む化合物およびその使用方法 |
| US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| AU2002339810A1 (en) * | 2001-10-16 | 2003-04-28 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US20040048795A1 (en) * | 2002-02-26 | 2004-03-11 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| US7273872B2 (en) | 2002-12-06 | 2007-09-25 | The Feinstein Institute For Medical Research | Inhibition of inflammation using α 7 receptor-binding cholinergic agonists |
| BRPI0412382A (pt) * | 2003-07-08 | 2006-09-19 | Astrazeneca Ab | composto , método para a verificação de novos compostos medicinais que se ligam a e modulam a atividade, por agonismo , agonismo parcial, ou antagonismo, do receptor de acetilcolina nicotìnico alfa7, método de tratamento ou profilaxia de uma doença ou condição humana, método para tratamento de jetlag, induzindo interrupção de fumar, vìcio em nicotina, abstinência, dor, e para colite ulcerativa, composição farmacêutica, e, método de tratamento ou prevenção de uma condição ou distúrbio que surge da disfunção de neurotransmissão do receptor de acetilcolina nicotìnico em um mamìfero, e, uso de um composto |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| AU2005225458B2 (en) | 2004-03-25 | 2008-12-04 | The Feinstein Institutes For Medical Research | Neural tourniquet |
| MX2007006743A (es) * | 2004-12-15 | 2007-07-09 | Astrazeneca Ab | Ligandos del receptor de acetilcolina nicotinica. |
| ATE489132T1 (de) | 2004-12-27 | 2010-12-15 | The Feinstein Inst Medical Res | Behandlung von entzündlichen erkrankungen durch elektrische stimulation des vagus-nervs |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| WO2006071184A1 (en) * | 2004-12-28 | 2006-07-06 | Astrazeneca Ab | Aryl sulphonamide modulators |
| AU2006282896A1 (en) * | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| RU2326787C2 (ru) * | 2005-11-09 | 2008-06-20 | Сергей Федорович Бокарев | Способ управления крылом, помещенным в текучую среду, при его взаимодействии с этой средой и устройство для его осуществления |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| EP2255848A3 (en) | 2006-09-04 | 2011-04-06 | NeuroSearch AS | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| DE102008015999B4 (de) | 2008-03-27 | 2011-04-21 | Novar Gmbh | Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage |
| US9211409B2 (en) * | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| US7863291B2 (en) * | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
| RS52703B (sr) | 2008-06-20 | 2013-08-30 | Astrazeneca Ab | Derivat dibenzotiazepina i njegova upotreba |
| ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
| MY173229A (en) | 2008-11-19 | 2020-01-07 | Forum Pharmaceuticals Inc | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| US8507516B2 (en) | 2009-10-28 | 2013-08-13 | Bristol-Myers Squibb Company | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US8278320B2 (en) | 2009-10-28 | 2012-10-02 | Bristol-Myers Squibb Company | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| EP2515996B1 (en) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| CN103025744A (zh) | 2010-04-30 | 2013-04-03 | 百时美施贵宝公司 | 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物 |
| PT3029039T (pt) | 2010-05-17 | 2017-11-28 | Forum Pharmaceuticals Inc | Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート |
| EA029430B1 (ru) | 2013-06-21 | 2018-03-30 | Такеда Фармасьютикл Компани Лимитед | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| CN114904142A (zh) | 2016-01-20 | 2022-08-16 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| US10661112B2 (en) | 2016-07-25 | 2020-05-26 | Tonal Systems, Inc. | Digital strength training |
| US11745039B2 (en) | 2016-07-25 | 2023-09-05 | Tonal Systems, Inc. | Assisted racking of digital resistance |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| EP3668402B1 (en) | 2017-08-14 | 2024-07-31 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| US10335626B2 (en) | 2017-10-02 | 2019-07-02 | Tonal Systems, Inc. | Exercise machine with pancake motor |
| US10589163B2 (en) | 2017-10-02 | 2020-03-17 | Tonal Systems, Inc. | Exercise machine safety enhancements |
| US10617903B2 (en) | 2017-10-02 | 2020-04-14 | Tonal Systems, Inc. | Exercise machine differential |
| US10486015B2 (en) | 2017-10-02 | 2019-11-26 | Tonal Systems, Inc. | Exercise machine enhancements |
| US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| JP2023526080A (ja) | 2020-05-21 | 2023-06-20 | ザ・フェインステイン・インスティチュート・フォー・メディカル・リサーチ | 迷走神経刺激のためのシステムおよび方法 |
| US11285355B1 (en) | 2020-06-08 | 2022-03-29 | Tonal Systems, Inc. | Exercise machine enhancements |
| US11998804B2 (en) | 2021-04-27 | 2024-06-04 | Tonal Systems, Inc. | Repetition phase detection |
| US11878204B2 (en) | 2021-04-27 | 2024-01-23 | Tonal Systems, Inc. | First repetition detection |
| WO2022245878A1 (en) | 2021-05-17 | 2022-11-24 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH601304A5 (pt) * | 1974-02-12 | 1978-07-14 | Buskine Sa | |
| US4028351A (en) * | 1971-09-07 | 1977-06-07 | Buskine S.A. | Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained |
| SU495310A1 (ru) * | 1974-03-05 | 1975-12-15 | Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе | Хинуклидил-3-диарал(гетерил) карбинолы, про вл ющие антигистаминную, антисеротониновую и антиаллергическую активность и способ их получени |
| GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| GB8816299D0 (en) * | 1988-07-08 | 1988-08-10 | Merck Sharp & Dohme | Therapeutic agents |
| US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| IL97726A (en) * | 1990-04-10 | 1994-12-29 | Israel Inst Biolog Res | Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds |
| US5073560A (en) * | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
| US5137895A (en) * | 1991-04-29 | 1992-08-11 | A. H. Robins Company, Incorporated | 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols |
-
1995
- 1995-08-22 CZ CZ1997392A patent/CZ289512B6/cs not_active IP Right Cessation
- 1995-08-22 ES ES95930755T patent/ES2145922T3/es not_active Expired - Lifetime
- 1995-08-22 BR BR9508751A patent/BR9508751A/pt not_active IP Right Cessation
- 1995-08-22 KR KR1019970701159A patent/KR100366331B1/ko not_active Expired - Fee Related
- 1995-08-22 MX MX9701292A patent/MX9701292A/es unknown
- 1995-08-22 UA UA97031329A patent/UA54375C2/uk unknown
- 1995-08-22 DE DE69516524T patent/DE69516524T2/de not_active Expired - Fee Related
- 1995-08-22 SK SK216-97A patent/SK282366B6/sk not_active IP Right Cessation
- 1995-08-22 NZ NZ292289A patent/NZ292289A/en not_active IP Right Cessation
- 1995-08-22 US US08/525,575 patent/US5902814A/en not_active Expired - Fee Related
- 1995-08-22 JP JP50799596A patent/JP3708962B2/ja not_active Expired - Fee Related
- 1995-08-22 AT AT95930755T patent/ATE192157T1/de not_active IP Right Cessation
- 1995-08-22 EP EP95930755A patent/EP0777671B1/en not_active Expired - Lifetime
- 1995-08-22 PL PL95318760A patent/PL183933B1/pl not_active IP Right Cessation
- 1995-08-22 HU HU9701965A patent/HUT77352A/hu unknown
- 1995-08-22 EE EE9700039A patent/EE03399B1/xx not_active IP Right Cessation
- 1995-08-22 AU AU34018/95A patent/AU690735B2/en not_active Ceased
- 1995-08-22 PT PT95930755T patent/PT777671E/pt unknown
- 1995-08-22 CA CA002196995A patent/CA2196995C/en not_active Expired - Fee Related
- 1995-08-22 RU RU97104165A patent/RU2148058C1/ru not_active IP Right Cessation
- 1995-08-22 DK DK95930755T patent/DK0777671T3/da active
- 1995-08-22 WO PCT/SE1995/000937 patent/WO1996006098A1/en not_active Ceased
- 1995-08-22 CN CN95195518A patent/CN1056846C/zh not_active Expired - Fee Related
- 1995-08-23 IL IL11503995A patent/IL115039A/xx not_active IP Right Cessation
- 1995-08-23 EG EG70395A patent/EG24222A/xx active
- 1995-08-24 TR TR95/01053A patent/TR199501053A2/xx unknown
- 1995-08-24 TW TW084108836A patent/TW397837B/zh not_active IP Right Cessation
- 1995-11-08 SA SA95160370A patent/SA95160370B1/ar unknown
-
1997
- 1997-02-03 IS IS4424A patent/IS1852B/is unknown
- 1997-02-21 NO NO970800A patent/NO307707B1/no not_active IP Right Cessation
- 1997-02-24 FI FI970762A patent/FI112868B/fi active
-
1998
- 1998-11-09 US US09/188,099 patent/US6051581A/en not_active Expired - Fee Related
-
1999
- 1999-11-08 CN CN99123574A patent/CN1099419C/zh not_active Expired - Fee Related
-
2000
- 2000-04-10 AR ARP000101632A patent/AR031828A2/es unknown
- 2000-07-04 GR GR20000401563T patent/GR3033878T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9508751A (pt) | Composto formulação e processos de tratamento ou profilaxia de disfunções psicóticas ou disfunções de debilitação intelectual e da ansiedade e de preparação do composto | |
| EE04280B1 (et) | Imidasopürimidiinid ja imidasopüridiinid neuroloogiliste häirete käitlemiseks | |
| FI972781L (fi) | Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä | |
| BR9406128A (pt) | Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica | |
| FI971969A0 (fi) | Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä | |
| DE69725484D1 (de) | Vorrichtung zur Behandlung von Harninkontinenz | |
| EE9700267A (et) | a1L- agonistide kasutamine uriiniinkontinentsuse raviks | |
| HUP0400719A3 (en) | Compounds and methods for treatment and diagnosis of chlamydial infection | |
| FI952169A7 (fi) | Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi | |
| MA24437A1 (fr) | Procede de la preparation et de la formulation de dihydrate d'eprosartan | |
| GB2311940B (en) | Pharmaceutical compositions for the treatment of rhinitis | |
| ATE318604T1 (de) | Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen | |
| BR9506581A (pt) | Composto composição farmacêutica uso do composto processo para a profilaxia ou tratamento de uma condição clínica em um manífero por exemplo um humano e para a preparação de um composto e composto intermediário | |
| BR9605984A (pt) | Artigo higiênico capaz de aperfeiçoar o encaixe contra o corpo e método e aparelho para manufaturar o mesmo | |
| BR9710376A (pt) | Composto antiviral uso do mesmo composi-Æo farmac-utica e processo para tratamento antiviral profil tico ou terap-utico de um animal humano ou nÆo humano | |
| ID21948A (id) | Penggunaan 1-hidroksi-2piridon untuk pengobatan infeksi-infeksi kulit | |
| DE69620691D1 (de) | Therapeutisches Mittel zur Behandlung der Hypercholesterinämie | |
| FI940799A7 (fi) | Laite inkontinenssihoitoa varten | |
| ID27214A (id) | Triazolopiridina untuk pengobatan gangguan trombosis | |
| AU7310896A (en) | Use of nitroflavonoids for the treatment of anxiety | |
| BR9612234A (pt) | Composto processo para preparação do mesmo uso do composto e processos para tratamento de doenças das vias aéreas e tratamento ou profilaxia de glaucoma | |
| ATE230741T1 (de) | 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen | |
| HUP0102886A3 (en) | Treatment of anxiety disorders | |
| FI952203L (fi) | Sykloheksaanijohdannaiset, menetelmä niiden valmistamiseksi ja yhdisteiden käyttö sairauksien hoitamiseksi | |
| FI964019L (fi) | Kinolonijohdannainen virtsainkontinenssin hoitoon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| HJEG | Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law | ||
| FF | Decision: intention to grant | ||
| FG9A | Patent or certificate of addition granted | ||
| B24H | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi) | ||
| B24F | Patent annual fee: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE AS 15A, 16A, 17A, 18A, 19A E 20A ANUIDADES. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |